Pharma BD Deal Intelligence
Celgene agreed to acquire Abraxis for ~$2.9 billion ($58.00 cash plus 0.2617 Celgene shares and one CVR per share); Abraxane would establish Celgene in solid…
Celgene framed Abraxane as the centerpiece of a global oncology strategy, with CVR structure tied to lung and pancreatic milestones reflecting both confidence…
Roughly a year after the acquisition, coverage reported Celgene was sticking with Abraxane and continuing to invest in expanding its label, reflecting ongoing…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Celgene agreed to buy Abraxis BioScience for $2.9B in cash and stock plus tradeable CVR for future milestones/royalties. Each share received $58.00 cash + 0.2617 Celgene shares + 1 CVR.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Abraxis BioScience Inc. (this deal) | 2010 | $2.9B | 65 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2010 deals · Celgene Corporation deals · Oncology deals